Skip to main content
  • Register
  • Help
  • Contact us

Oxford Biomedica plc (OXB) Ordinary 50p

Sell:1,020.00p Buy:1,022.00p 0 Change: 18.00p (1.73%)
FTSE 250:1.26%
Market closed Prices as at close on 7 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:1,020.00p
Buy:1,022.00p
Change: 18.00p (1.73%)
Market closed Prices as at close on 7 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:1,020.00p
Buy:1,022.00p
Change: 18.00p (1.73%)
Market closed Prices as at close on 7 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Oxford BioMedica Plc is a gene and cell therapy company. The Company and its subsidiaries has developed lentiviral vector delivery platform (LentiVector), which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, liver and central nervous system (CNS) disorders. The Company's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401 and addresses neurodegenerative and a range of cancers. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

Contact details

Address:
Windrush Court, Transport Way
OXFORD
OX4 6LT
United Kingdom
Telephone:
+44 (01865) 783000
Website:
www.oxfordbiomedica.co.uk

Important dates

Future events
AGM 27 May 2021 27/05/21
Past events
Annual report 27 April 2021 27/04/21
Final results 15 April 2021 15/04/21
Interim results 17 September 2020 17/09/20
AGM 23 June 2020 23/06/20
Annual report 22 May 2020 22/05/20

General stock information

EPIC:
OXB
ISIN:
GB00BDFBVT43
Market cap:
£843.98 million
Shares in issue:
82.42 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE techMARK 100,FTSE 250,FTSE 350,FTSE All Share,FTSE techMARK All Share

Key personnel

  • John Dawson
    Chief Executive Officer, Executive Director
  • Stuart Paynter
    Chief Financial Officer, Director
  • Nick Page
    Chief Operating Officer
  • Helen Stephenson-Ellis
    Chief People Officer
  • James Miskin
    Chief Technical Officer
  • Kyriacos Mitrophanous
    Chief Scientific Officer
  • Natalie Walter
    General Counsel
  • Jason Slingsby
    Chief Business Officer
  • Dmitry Zamoryakhin
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.